Recombinant Anti-BAFF x Anti-IL17 Bispecific Antibody (Single-chain Diabody) (SCDB-019)

Recombinant Anti-BAFF x Anti-IL17 Bispecific Antibody (Single-chain Diabody) is designed to to be expressed as one polypeptide chain with four variable domains from two parental antibodies. The middle linker is long enough to form scFv dimers between the two diabody chains. This BsAb can neutralize both BAFF and IL- 17 simultaneously. It is designed for the research of Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA); Psoriasis (Ps); Ankylosing Spondylitis (AS); Psoriatic Arthritis (PA) primary Sjögren's Syndrome (pSS); Multiple Myeloma (MM) therapy.

Datasheet INQUIRY

Specifications

Targets

BAFF & IL17

Type

Single-chain Diabody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA); Psoriasis (Ps); Ankylosing Spondylitis (AS); Psoriatic Arthritis (PA) primary Sjögren's Syndrome (pSS); Multiple Myeloma (MM)

Targets

Target 1

BAFF

Gene ID

10673

UniProt ID

Q9Y275

Alternative Names

TNFSF13B; TNF superfamily member 13b; DTL; B cell activating factor; BAFF; BLYS; CD257; TALL1; THANK; ZTNF4; TALL-1; TNFSF20

Target 2

IL17

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-BAFF x Anti-IL17 Bispecific Antibody (Single-chain Diabody) (SCDB-019). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-BAFF x Anti-IL17 Bispecific Antibody (Single-chain Diabody) (CAT#: SCDB-019)

Specifications

Targets

Customer Reviews and Q&As